Agilent Technologies Inc. (A) Q3 FY2026 Financial Statements: Revenue $1.88B, Net income $362.00M
More for Agilent Technologies: Company index · 10-K and 10-Q summary · 8-K filings and events
PeriodQ3 FY2026
Published
Agilent Technologies reported $1.88 billion in revenue for Q3 FY2026, the quarter ended July 31, 2026, up 8.1% from a year earlier, with growth in all three of its segments. Income from operations was $444 million, up 23.3%, helped by higher volume, targeted price increases, favorable mix and refunds of tariffs it had previously paid. Net income was $362 million, or $1.28 per diluted share, against $336 million, or $1.18, a smaller gain because Agilent's effective tax rate rose, partly because a tax reserve release had lowered it in the year-ago quarter.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $1,878,000,000 | up 8.1% |
| Net income | $362,000,000 | up 7.7% |
| Diluted EPS | $1.28 | up 8.5% |
| Operating income | $444,000,000 | up 23.3% |
Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. Figures calculated here, such as margins, free cash flow and trailing-twelve-month totals, have no line in a filing to point to and are not linked.
About this file
| Ticker | A |
|---|---|
| CIK | 0001090872 |
| Company | Agilent Technologies Inc. |
| Business type | industrial |
| Schema template | standard (life-science and diagnostic instruments, consumables and services): revenue split into products and services, cost of revenue, gross profit, operating income, net income, EPS; cash, debt, assets, equity; operating cash flow, capital expenditures, free cash flow, dividends; revenue and operating income by reportable segment |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual US dollars (not millions); per-share amounts in dollars; weighted-average share counts in actual shares (the statements print them rounded to the nearest million); shares outstanding in actual shares |
A annual income statement, balance sheet and cash flow
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Period start | 2024-11-01 | 2023-11-01 | 2022-11-01 |
| Period end | 2025-10-31 | 2024-10-31 | 2023-10-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 10-K | 10-K | 10-K |
| Income statement | |||
| Product revenue | 4,944,000,000 | 4,672,000,000 | 5,051,000,000 |
| Services and other revenue | 2,004,000,000 | 1,838,000,000 | 1,782,000,000 |
| Total net revenue | 6,948,000,000 | 6,510,000,000 | 6,833,000,000 |
| Cost of products | 2,237,000,000 | 2,024,000,000 | 2,428,000,000 |
| Cost of services and other | 1,068,000,000 | 951,000,000 | 940,000,000 |
| Total cost of revenue | 3,305,000,000 | 2,975,000,000 | 3,368,000,000 |
| Research and development | 455,000,000 | 479,000,000 | 481,000,000 |
| Selling general and administrative | 1,709,000,000 | 1,568,000,000 | 1,634,000,000 |
| Total costs and expenses | 5,469,000,000 | 5,022,000,000 | 5,483,000,000 |
| Operating income | 1,479,000,000 | 1,488,000,000 | 1,350,000,000 |
| Interest income | 62,000,000 | 80,000,000 | 51,000,000 |
| Interest expense | -112,000,000 | -96,000,000 | -95,000,000 |
| Other income expense net | 6,000,000 | 49,000,000 | 33,000,000 |
| Income before taxes | 1,435,000,000 | 1,521,000,000 | 1,339,000,000 |
| Provision for income taxes | 132,000,000 | 232,000,000 | 99,000,000 |
| Net income | 1,303,000,000 | 1,289,000,000 | 1,240,000,000 |
| Basic EPS | 4.59 | 4.44 | 4.22 |
| Diluted EPS | 4.57 | 4.43 | 4.19 |
| Basic shares | 284,000,000 | 290,000,000 | 294,000,000 |
| Diluted shares | 285,000,000 | 291,000,000 | 296,000,000 |
| Gross profit | 3,643,000,000 | 3,535,000,000 | 3,465,000,000 |
| Balance sheet | |||
| Cash and cash equivalents | 1,789,000,000 | 1,329,000,000 | |
| Accounts receivable net | 1,487,000,000 | 1,324,000,000 | |
| Inventory | 1,025,000,000 | 972,000,000 | |
| Other current assets | 293,000,000 | 334,000,000 | |
| Total current assets | 4,594,000,000 | 3,959,000,000 | |
| Property plant and equipment net | 2,023,000,000 | 1,778,000,000 | |
| Goodwill | 4,473,000,000 | 4,477,000,000 | |
| Other intangible assets net | 445,000,000 | 547,000,000 | |
| Long term investments | 133,000,000 | 175,000,000 | |
| Other assets | 1,059,000,000 | 910,000,000 | |
| Total assets | 12,727,000,000 | 11,846,000,000 | |
| Accounts payable | 570,000,000 | 540,000,000 | |
| Employee compensation and benefits | 443,000,000 | 368,000,000 | |
| Deferred revenue | 624,000,000 | 544,000,000 | |
| Short term debt | 304,000,000 | 45,000,000 | |
| Other accrued liabilities | 406,000,000 | 398,000,000 | |
| Total current liabilities | 2,347,000,000 | 1,895,000,000 | |
| Long term debt | 3,050,000,000 | 3,345,000,000 | |
| Retirement and post retirement benefits | 126,000,000 | 130,000,000 | |
| Other long term liabilities | 463,000,000 | 578,000,000 | |
| Total liabilities | 5,986,000,000 | 5,948,000,000 | |
| Total stockholders equity | 6,741,000,000 | 5,898,000,000 | |
| Total debt | 3,354,000,000 | 3,390,000,000 | |
| Shares outstanding | 283,054,377 | 285,193,011 | |
| Cash flow | |||
| Depreciation and amortization | 288,000,000 | 257,000,000 | 271,000,000 |
| Share based compensation | 128,000,000 | 129,000,000 | 111,000,000 |
| Operating cash flow | 1,559,000,000 | 1,751,000,000 | 1,772,000,000 |
| Capital expenditures | -407,000,000 | -378,000,000 | -298,000,000 |
| Acquisitions net of cash acquired | 4,000,000 | -862,000,000 | -51,000,000 |
| Investing cash flow | -394,000,000 | -1,258,000,000 | -310,000,000 |
| Repurchase of common stock | -425,000,000 | -1,150,000,000 | -575,000,000 |
| Dividends paid | -282,000,000 | -274,000,000 | -265,000,000 |
| Proceeds from issuance of long term debt | 4,000,000 | 1,197,000,000 | 0 |
| Repayment of long term debt | -3,000,000 | -600,000,000 | 0 |
| Financing cash flow | -715,000,000 | -752,000,000 | -930,000,000 |
| Free cash flow | 1,152,000,000 | 1,373,000,000 | 1,474,000,000 |
| Segments | |||
| Life sciences and diagnostics markets | |||
| Net revenue | 2,726,000,000 | 2,466,000,000 | 2,780,000,000 |
| Income from operations | 536,000,000 | 484,000,000 | 673,000,000 |
| Agilent crosslab | |||
| Net revenue | 2,908,000,000 | 2,747,000,000 | 2,656,000,000 |
| Income from operations | 946,000,000 | 925,000,000 | 839,000,000 |
| Applied markets | |||
| Net revenue | 1,314,000,000 | 1,297,000,000 | 1,397,000,000 |
| Income from operations | 301,000,000 | 312,000,000 | 363,000,000 |
| Total reportable segment income from operations | 1,783,000,000 | 1,721,000,000 | 1,875,000,000 |
| Per share | |||
| Dividends declared per share | 0.992 | 0.944 | 0.900 |
A quarterly income statement, balance sheet and cash flow
| Q3 FY2026 | Q3 FY2025 | |
|---|---|---|
| Fiscal quarter | 3 | 3 |
| Period start | 2026-05-01 | 2025-05-01 |
| Period end | 2026-07-31 | 2025-07-31 |
| Period type | three months | three months |
| Source accession | 10-Q | 10-Q |
| Income statement | ||
| Product revenue | 1,333,000,000 | 1,230,000,000 |
| Services and other revenue | 545,000,000 | 508,000,000 |
| Total net revenue | 1,878,000,000 | 1,738,000,000 |
| Cost of products | 559,000,000 | 577,000,000 |
| Cost of services and other | 277,000,000 | 273,000,000 |
| Total cost of revenue | 836,000,000 | 850,000,000 |
| Research and development | 123,000,000 | 111,000,000 |
| Selling general and administrative | 475,000,000 | 417,000,000 |
| Total costs and expenses | 1,434,000,000 | 1,378,000,000 |
| Operating income | 444,000,000 | 360,000,000 |
| Interest income | 15,000,000 | 16,000,000 |
| Interest expense | -29,000,000 | -28,000,000 |
| Other income expense net | 14,000,000 | 18,000,000 |
| Income before taxes | 444,000,000 | 366,000,000 |
| Provision for income taxes | 82,000,000 | 30,000,000 |
| Net income | 362,000,000 | 336,000,000 |
| Basic EPS | 1.28 | 1.18 |
| Diluted EPS | 1.28 | 1.18 |
| Basic shares | 282,000,000 | 284,000,000 |
| Diluted shares | 283,000,000 | 285,000,000 |
| Gross profit | 1,042,000,000 | 888,000,000 |
| Balance sheet | ||
| Cash and cash equivalents | 1,758,000,000 | |
| Accounts receivable net | 1,478,000,000 | |
| Inventory | 1,117,000,000 | |
| Other current assets | 340,000,000 | |
| Total current assets | 4,693,000,000 | |
| Property plant and equipment net | 2,134,000,000 | |
| Goodwill | 5,030,000,000 | |
| Other intangible assets net | 906,000,000 | |
| Long term investments | 130,000,000 | |
| Other assets | 1,074,000,000 | |
| Total assets | 13,967,000,000 | |
| Accounts payable | 608,000,000 | |
| Employee compensation and benefits | 423,000,000 | |
| Deferred revenue | 640,000,000 | |
| Short term debt | 304,000,000 | |
| Other accrued liabilities | 314,000,000 | |
| Total current liabilities | 2,289,000,000 | |
| Long term debt | 3,645,000,000 | |
| Retirement and post retirement benefits | 128,000,000 | |
| Other long term liabilities | 542,000,000 | |
| Total liabilities | 6,604,000,000 | |
| Total stockholders equity | 7,363,000,000 | |
| Total debt | 3,949,000,000 | |
| Shares outstanding | 281,965,813 | |
| Segments | ||
| Life sciences and diagnostics markets | ||
| Net revenue | 746,000,000 | 670,000,000 |
| Income from operations | 176,000,000 | 118,000,000 |
| Agilent crosslab | ||
| Net revenue | 786,000,000 | 744,000,000 |
| Income from operations | 270,000,000 | 248,000,000 |
| Applied markets | ||
| Net revenue | 346,000,000 | 324,000,000 |
| Income from operations | 86,000,000 | 71,000,000 |
| Total reportable segment income from operations | 532,000,000 | 437,000,000 |
| Per share | ||
| Dividends declared per share | 0.255 | 0.248 |
A year-to-date income statement and cash flow
| Nine months ended July 31, 2026 (first nine months of FY2026) | Nine months ended July 31, 2025 (first nine months of FY2025) | |
|---|---|---|
| Period start | 2025-11-01 | 2024-11-01 |
| Period end | 2026-07-31 | 2025-07-31 |
| Period type | nine months | nine months |
| Source accession | 10-Q | 10-Q |
| Income statement | ||
| Product revenue | 3,911,000,000 | 3,616,000,000 |
| Services and other revenue | 1,600,000,000 | 1,471,000,000 |
| Total net revenue | 5,511,000,000 | 5,087,000,000 |
| Cost of products | 1,697,000,000 | 1,650,000,000 |
| Cost of services and other | 836,000,000 | 784,000,000 |
| Total cost of revenue | 2,533,000,000 | 2,434,000,000 |
| Research and development | 366,000,000 | 336,000,000 |
| Selling general and administrative | 1,416,000,000 | 1,281,000,000 |
| Total costs and expenses | 4,315,000,000 | 4,051,000,000 |
| Operating income | 1,196,000,000 | 1,036,000,000 |
| Interest income | 43,000,000 | 45,000,000 |
| Interest expense | -79,000,000 | -85,000,000 |
| Other income expense net | 56,000,000 | -3,000,000 |
| Income before taxes | 1,216,000,000 | 993,000,000 |
| Provision for income taxes | 210,000,000 | 124,000,000 |
| Net income | 1,006,000,000 | 869,000,000 |
| Basic EPS | 3.55 | 3.05 |
| Diluted EPS | 3.55 | 3.05 |
| Basic shares | 283,000,000 | 285,000,000 |
| Diluted shares | 283,000,000 | 285,000,000 |
| Gross profit | 2,978,000,000 | 2,653,000,000 |
| Cash flow | ||
| Depreciation and amortization | 200,000,000 | 217,000,000 |
| Share based compensation | 105,000,000 | 102,000,000 |
| Operating cash flow | 1,064,000,000 | 1,014,000,000 |
| Capital expenditures | -249,000,000 | -314,000,000 |
| Acquisitions net of cash acquired | -950,000,000 | 4,000,000 |
| Investing cash flow | -1,202,000,000 | -304,000,000 |
| Repurchase of common stock | -295,000,000 | -340,000,000 |
| Dividends paid | -216,000,000 | -212,000,000 |
| Proceeds from issuance of long term debt | 600,000,000 | 4,000,000 |
| Repayment of long term debt | -4,000,000 | -2,000,000 |
| Financing cash flow | 105,000,000 | -515,000,000 |
| Free cash flow | 815,000,000 | 700,000,000 |
| Segments | ||
| Life sciences and diagnostics markets | ||
| Net revenue | 2,157,000,000 | 1,971,000,000 |
| Income from operations | 446,000,000 | 364,000,000 |
| Agilent crosslab | ||
| Net revenue | 2,303,000,000 | 2,153,000,000 |
| Income from operations | 752,000,000 | 700,000,000 |
| Applied markets | ||
| Net revenue | 1,051,000,000 | 963,000,000 |
| Income from operations | 259,000,000 | 214,000,000 |
| Total reportable segment income from operations | 1,457,000,000 | 1,278,000,000 |
| Per share | ||
| Dividends declared per share | 0.765 | 0.744 |
A trailing twelve month income statement and cash flow
| Twelve months ended July 31, 2026 | |
|---|---|
| Period start | 2025-08-01 |
| Period end | 2026-07-31 |
| Period type | trailing twelve months |
| Source accession | 10-Q |
| Derived from accessions | 10-K, 10-Q |
| Income statement | |
| Gross profit | 3,968,000,000 |
| Product revenue | 5,239,000,000 |
| Services and other revenue | 2,133,000,000 |
| Total net revenue | 7,372,000,000 |
| Total cost of revenue | 3,404,000,000 |
| Operating income | 1,639,000,000 |
| Income before taxes | 1,658,000,000 |
| Provision for income taxes | 218,000,000 |
| Net income | 1,440,000,000 |
| Cash flow | |
| Free cash flow | 1,267,000,000 |
| Depreciation and amortization | 271,000,000 |
| Operating cash flow | 1,609,000,000 |
| Capital expenditures | -342,000,000 |
- Derivation. FY2025 (Form 10-K, accession 0001090872-25-000087) plus the nine months ended July 31, 2026 less the nine months ended July 31, 2025 (Form 10-Q, accession 0001090872-26-000064)
Adjustments
| Splits applied | none |
|---|---|
| Splits note | No stock split falls within or between the periods presented, so no per-share restatement was applied. |
| ADR ratio | n/a |
| FX | None. Agilent reports in US dollars. |
Notes
- Agilent's fiscal year ends October 31 and its fiscal quarters end January 31, April 30 and July 31. FY2025 is the year ended October 31, 2025; Q3 FY2026 is the three months ended July 31, 2026.
- Annual figures (FY2025, FY2024 and FY2023) are from the FY2025 Form 10-K (accession 0001090872-25-000087). That report prints three years of income statement and cash flow but only two balance sheets, so FY2023 carries no balance sheet.
- Quarterly, nine-month and July 31, 2026 balance sheet figures are from the Q3 FY2026 Form 10-Q (accession 0001090872-26-000064). The 10-Q's October 31, 2025 balance sheet column matches the 10-K's FY2025 balance sheet line for line.
- Template: standard industrial. Agilent sells laboratory instruments, consumables, software and services; revenue is reported as products plus services and other, and the statements present costs of products and of services but no gross profit line.
- Gross profit is derived as total net revenue less total costs (cost of products plus cost of services and other), as the statements print no gross profit line. Free cash flow is derived as net cash provided by operating activities less payments to acquire property, plant and equipment; Agilent's statements do not present a free cash flow figure. Total debt is short-term debt plus long-term debt as printed on the balance sheet.
- Weighted-average share counts are printed in millions, rounded to the nearest million, so they are stated here to that precision. Shares outstanding are the exact counts printed in the balance sheet's common stock caption.
- Dividends declared per share are taken from the statements of equity: $0.992 (FY2025), $0.944 (FY2024), $0.900 (FY2023), $0.255 (Q3 FY2026), $0.248 (Q3 FY2025), $0.765 (nine months of FY2026) and $0.744 (nine months of FY2025).
- The 10-Q prints its cash flow statement for the nine months only, so cash flow figures appear in the nine-month and trailing-twelve-month views rather than on the quarterly entries.
- The trailing twelve months ended July 31, 2026 are derived as FY2025 plus the nine months ended July 31, 2026 less the nine months ended July 31, 2025. Per-share amounts are not derived for this view.
- Segment figures are each reportable segment's net revenue and income from operations as reported in the segment note. Segment income from operations excludes restructuring, intangible amortization, transformational initiatives, acquisition and integration costs and other unallocated items, so the three segments sum to more than consolidated GAAP income from operations (for Q3 FY2026, $532 million of segment income against $444 million GAAP). Segment revenue sums to consolidated net revenue in every period.
- Segment structure: in November 2024 Agilent reorganized into Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, and the FY2025 10-K recast FY2024 and FY2023 segment results to that structure.
- On June 24, 2026 Agilent acquired BC Midco I, Inc. (Biocare) for net consideration of $950 million, which accounts for the nine-month cash outflow for acquisitions and most of the increase in goodwill and other intangible assets since October 31, 2025. Biocare's results are included in the Life Sciences and Diagnostics Markets segment from the acquisition date.
- No stock split occurred in the periods presented and Agilent is not an ADR issuer, so per-share figures are as filed, per share of common stock.
Uncertainties
- No discrete three-month cash flow figures are available for Q3 FY2026 or Q3 FY2025: the Q3 FY2026 10-Q and its accompanying earnings release (accession 0001090872-26-000062) print the cash flow statement for the nine months only. Quarterly operating cash flow, capital expenditures and free cash flow are therefore not reported here.
- The FY2023 balance sheet is not presented in the FY2025 10-K, so no FY2023 balance sheet figures are reported.
Company details
| Name | Agilent Technologies, Inc. |
|---|---|
| Ticker | A |
| CIK | 0001090872 |
| Exchange | NYSE |
| State | California |
| Incorporation | Delaware |
| SIC | 3826 |
| Office | Industrial Applications and Services |
| Industry | Laboratory Analytical Instruments |
Fiscal period
| Fiscal year | 2026 |
|---|---|
| Fiscal period | Q3 |
| Tag | FY26Q3 |
| Period end | 2026-07-31 |
| Form | 10-Q |
| Accession | 0001090872-26-000064 |
| Fiscal year end | 1031 |
| Source | facts |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Source |
|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2025 | FY | FY25 | 2025-10-31 | 2025-12-22 | 0001090872-25-000087 | reported |
| quarterly | yes | 10-Q | 2026 | Q3 | FY26Q3 | 2026-07-31 | 2026-09-01 | 0001090872-26-000064 | facts |
FAQ · Agilent Technologies financial statements
How much revenue did Agilent report in Q3 FY2026?
Agilent Technologies reported $1.88 billion in revenue for Q3 FY2026, the quarter ended July 31, 2026. That is up 8.1% from $1.74 billion in the same quarter a year earlier, with all three of its segments growing.
What was Agilent's net income in Q3 FY2026?
Agilent Technologies earned net income of $362 million in Q3 FY2026, the quarter ended July 31, 2026, up 7.7% from $336 million a year earlier. Net income grew more slowly than income from operations because Agilent's effective tax rate rose, partly because a tax reserve release had lowered it in the year-ago quarter.
What was Agilent's earnings per share in Q3 FY2026?
Agilent Technologies reported diluted earnings per share of $1.28 for Q3 FY2026, the quarter ended July 31, 2026, up 8.5% from $1.18 in the same quarter a year earlier.
Why did Agilent's operating income rise in Q3 FY2026?
Agilent Technologies' income from operations was $444 million in Q3 FY2026, up 23.3% from $360 million a year earlier. The company attributed its higher operating margin to higher sales volume, a net benefit from refunds of tariffs it had previously paid and lower restructuring costs, partly offset by higher wages, variable pay and higher costs from transformational initiatives.
Where can I get Agilent Technologies Inc. (A) financial data in machine-readable form?
Ticker Scout publishes Agilent Technologies Inc.'s financial statements as JSON at https://tickerscout.ai/a/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/a/narrative.md and https://tickerscout.ai/a/events.md. Agilent Technologies Inc.'s SEC CIK is 0001090872. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Agilent Technologies Inc. (A) next file with the SEC?
Agilent Technologies Inc. (A) is expected to file its next Form 10-K with the SEC on or around December 21, 2026. That date is a projection rather than a company-announced date: it is derived from Agilent Technologies Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q3 FY2026, the period ended 2026-07-31, SEC accession 0001090872-26-000064.
Related companies
How this page was built
This page was built from three of Agilent Technologies Inc.'s own filings with the SEC, read one at a time. Nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names two such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from Agilent Technologies Inc.'s SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.